Becton Dickinson Collaborates with Ypsomed on New Syringe
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 23 2024
0mins
Should l Buy BDX?
Becton Dickinson and Co (BDX) has hit a 5-day low amid a broader market trend where the Nasdaq-100 is up 0.25% and the S&P 500 is up 0.01%.
The company recently announced a collaboration with Ypsomed to develop a 5.5mL syringe aimed at enhancing self-administration efficiency for patients. This product innovation is expected to meet the growing demand for large-volume subcutaneous injections, featuring an 8mm short needle and thinner wall cannulas to improve injection times and optimize flow. The partnership is poised to drive market growth in high-dose biopharmaceuticals, with syringe samples expected by mid-2026.
This collaboration highlights BDX's commitment to addressing patient needs in the high-dose biologics space, potentially positioning the company favorably in a competitive market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BDX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BDX
Wall Street analysts forecast BDX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDX is 202.38 USD with a low forecast of 183.00 USD and a high forecast of 220.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
3 Buy
5 Hold
0 Sell
Moderate Buy
Current: 206.510
Low
183.00
Averages
202.38
High
220.00
Current: 206.510
Low
183.00
Averages
202.38
High
220.00
About BDX
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. Its BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, advanced monitoring, and pharmaceutical systems. Its BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. Its BD Interventional segment provides vascular, urology, oncology and surgical specialty products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Becton Dickinson Q1 Earnings Forecast
- Earnings Release Announcement: Becton Dickinson is set to release its Q1 earnings before the market opens on February 9, with analysts projecting earnings of $2.81 per share, down from $3.43 last year, indicating a potential decline in profitability that may affect investor confidence.
- Revenue Expectations Decline: The company anticipates quarterly revenue of $5.15 billion, slightly lower than last year's $5.17 billion, reflecting soft market demand that could pressure stock prices and influence future investment decisions.
- Share Buyback Plan: Announced on January 27, Becton Dickinson's plan to repurchase up to 10 million shares aims to enhance earnings per share and shareholder returns, potentially attracting more investor interest in the company's long-term value.
- Dividend Yield Analysis: With an annual dividend yield of 2.03% and a quarterly dividend of $1.05, investors seeking $500 monthly dividends would need to invest approximately $295,103, highlighting the company's dividend policy's appeal to income-focused investors.
See More
Key Focus Areas This Week: Jobs, Consumer Prices, Coca-Cola, CVS, Ford, McDonald's, and More
- Market Performance: The Dow Jones Industrial Average rose by 2.5% and closed above 50,000 for the first time.
- Nasdaq Struggles: In contrast, the Nasdaq Composite ended the week down 1.8%, despite a strong rally on Friday.
See More
U.S. Jobs and Inflation Data Set for Release
- Job Data Expectations: The U.S. is expected to add 60,000 jobs in January, up from 50,000 in December, which could influence the Fed's monetary policy direction amidst ongoing economic uncertainty.
- Inflation Metrics Analysis: The January Consumer Price Index is projected to rise by 0.29% month-over-month and 2.5% year-over-year, showing improvement but still falling short of the Fed's 2% target, potentially affecting investor rate expectations.
- Market Reaction and Risks: Recent signs of labor market weakness, including an ADP report indicating only 22,000 new private sector jobs, may heighten expectations for further Fed rate cuts, although investors remain optimistic about economic resilience.
- Stock Market Rotation Trend: A significant rotation within the stock market is underway, with the Dow Jones Industrial Average rising over 2% this week, reflecting confidence in economic recovery, despite ongoing weakness in tech stocks.
See More
Becton, Dickinson Set to Release Q1 Earnings on February 9
- Earnings Announcement Date: Becton, Dickinson (BDX) is set to announce its Q1 2023 earnings on February 9 before market open, with consensus EPS estimate at $2.81, reflecting an 18.1% year-over-year decline, and revenue estimate at $5.15 billion, down 0.4% year-over-year, indicating profitability challenges ahead.
- Historical Performance Review: Over the past two years, BDX has consistently beaten EPS estimates 100% of the time and revenue estimates 63% of the time, demonstrating a degree of financial stability despite current pressures.
- Expectation Revisions: In the last three months, there have been no upward revisions to EPS estimates, with 9 downward adjustments, while revenue estimates also saw no upward revisions and 7 downward adjustments, reflecting market caution regarding the company's future performance.
- Dividend Declaration: Becton, Dickinson has declared a dividend of $1.05 per share, maintaining its commitment to shareholders despite profitability pressures, which underscores the stability of its cash flow.
See More
Citi Resumes Buy Rating on Becton, Dickinson
- Business Focus Enhancement: Citi has resumed its buy rating on Becton, Dickinson, asserting that the spinoff of its Biosciences & Diagnostic Solutions business on February 9 will allow the company to concentrate on medtech, leading to faster growth.
- Price Target Set: Citi has set a price target of $233 for BD, indicating a 15% upside based on the February 2 close, reflecting market optimism regarding its future growth potential.
- Increased Financial Flexibility: Analyst Joanne Wuensch noted that post-spinoff, BD will focus on four major areas: medical essentials, connected care, biopharma systems, and interventional, which is expected to enhance financial flexibility for debt repayment and share repurchase.
- R&D Investment Opportunities: Valued at $17.5 billion, the spinoff is anticipated to provide BD with additional funds for R&D investments, further driving innovation and competitiveness in the medtech sector.
See More
IHI Stock 52-Week Performance Analysis
- Price Range Analysis: IHI's stock has a 52-week low of $52.9047 and a high of $65.18, with the latest trade at $59.62, indicating significant price fluctuations that reflect market interest and investor sentiment.
- Technical Analysis Tool: Comparing the latest stock price to the 200-day moving average provides investors with valuable insights for technical analysis, helping them assess price trends and potential buy or sell opportunities to optimize investment decisions.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, reflecting dynamic market liquidity and investor behavior.
- Inflows and Outflows Monitoring: Weekly monitoring of ETFs for notable inflows (new units created) or outflows (old units destroyed) can impact the underlying stocks held within ETFs, influencing overall market performance and investor strategies.
See More
Becton Dickinson Q1 Earnings Forecast
- Earnings Release Announcement: Becton Dickinson is set to release its Q1 earnings before the market opens on February 9, with analysts projecting earnings of $2.81 per share, down from $3.43 last year, indicating a potential decline in profitability that may affect investor confidence.
- Revenue Expectations Decline: The company anticipates quarterly revenue of $5.15 billion, slightly lower than last year's $5.17 billion, reflecting soft market demand that could pressure stock prices and influence future investment decisions.
- Share Buyback Plan: Announced on January 27, Becton Dickinson's plan to repurchase up to 10 million shares aims to enhance earnings per share and shareholder returns, potentially attracting more investor interest in the company's long-term value.
- Dividend Yield Analysis: With an annual dividend yield of 2.03% and a quarterly dividend of $1.05, investors seeking $500 monthly dividends would need to invest approximately $295,103, highlighting the company's dividend policy's appeal to income-focused investors.
See More
Key Focus Areas This Week: Jobs, Consumer Prices, Coca-Cola, CVS, Ford, McDonald's, and More
- Market Performance: The Dow Jones Industrial Average rose by 2.5% and closed above 50,000 for the first time.
- Nasdaq Struggles: In contrast, the Nasdaq Composite ended the week down 1.8%, despite a strong rally on Friday.
See More
U.S. Jobs and Inflation Data Set for Release
- Job Data Expectations: The U.S. is expected to add 60,000 jobs in January, up from 50,000 in December, which could influence the Fed's monetary policy direction amidst ongoing economic uncertainty.
- Inflation Metrics Analysis: The January Consumer Price Index is projected to rise by 0.29% month-over-month and 2.5% year-over-year, showing improvement but still falling short of the Fed's 2% target, potentially affecting investor rate expectations.
- Market Reaction and Risks: Recent signs of labor market weakness, including an ADP report indicating only 22,000 new private sector jobs, may heighten expectations for further Fed rate cuts, although investors remain optimistic about economic resilience.
- Stock Market Rotation Trend: A significant rotation within the stock market is underway, with the Dow Jones Industrial Average rising over 2% this week, reflecting confidence in economic recovery, despite ongoing weakness in tech stocks.
See More
Becton, Dickinson Set to Release Q1 Earnings on February 9
- Earnings Announcement Date: Becton, Dickinson (BDX) is set to announce its Q1 2023 earnings on February 9 before market open, with consensus EPS estimate at $2.81, reflecting an 18.1% year-over-year decline, and revenue estimate at $5.15 billion, down 0.4% year-over-year, indicating profitability challenges ahead.
- Historical Performance Review: Over the past two years, BDX has consistently beaten EPS estimates 100% of the time and revenue estimates 63% of the time, demonstrating a degree of financial stability despite current pressures.
- Expectation Revisions: In the last three months, there have been no upward revisions to EPS estimates, with 9 downward adjustments, while revenue estimates also saw no upward revisions and 7 downward adjustments, reflecting market caution regarding the company's future performance.
- Dividend Declaration: Becton, Dickinson has declared a dividend of $1.05 per share, maintaining its commitment to shareholders despite profitability pressures, which underscores the stability of its cash flow.
See More
Citi Resumes Buy Rating on Becton, Dickinson
- Business Focus Enhancement: Citi has resumed its buy rating on Becton, Dickinson, asserting that the spinoff of its Biosciences & Diagnostic Solutions business on February 9 will allow the company to concentrate on medtech, leading to faster growth.
- Price Target Set: Citi has set a price target of $233 for BD, indicating a 15% upside based on the February 2 close, reflecting market optimism regarding its future growth potential.
- Increased Financial Flexibility: Analyst Joanne Wuensch noted that post-spinoff, BD will focus on four major areas: medical essentials, connected care, biopharma systems, and interventional, which is expected to enhance financial flexibility for debt repayment and share repurchase.
- R&D Investment Opportunities: Valued at $17.5 billion, the spinoff is anticipated to provide BD with additional funds for R&D investments, further driving innovation and competitiveness in the medtech sector.
See More
IHI Stock 52-Week Performance Analysis
- Price Range Analysis: IHI's stock has a 52-week low of $52.9047 and a high of $65.18, with the latest trade at $59.62, indicating significant price fluctuations that reflect market interest and investor sentiment.
- Technical Analysis Tool: Comparing the latest stock price to the 200-day moving average provides investors with valuable insights for technical analysis, helping them assess price trends and potential buy or sell opportunities to optimize investment decisions.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, reflecting dynamic market liquidity and investor behavior.
- Inflows and Outflows Monitoring: Weekly monitoring of ETFs for notable inflows (new units created) or outflows (old units destroyed) can impact the underlying stocks held within ETFs, influencing overall market performance and investor strategies.
See More
